Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?

By Reiji Anasako The Japanese diabetes market has seen an increasing number of fixed-dose combination drugs pairing dipeptidyl peptidase-4 (DPP-4) inhibitors with other agents with different mechanisms of action. Following DPP-4 combos with biguanides and thiazolidinediones, Canalia (teneligliptin + canagliflozin)...read more